Atara Biotherapeutics Inc's shares dropped 54% to $6.24, hitting a 20-day low, following the receipt of an FDA Complete Response Letter citing concerns over clinical trial adequacy.
The FDA's Complete Response Letter indicates that Atara's clinical trials may not have met the necessary standards, which could lead to significant financial and operational challenges for the company. This news has contributed to a sharp decline in investor confidence, resulting in a substantial drop in the stock price amid broader market weakness.
The implications of this FDA response are severe, as it not only affects Atara's current projects but also raises questions about future developments and investor trust in the company's ability to navigate regulatory hurdles.
Wall Street analysts forecast ATRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 21.50 USD with a low forecast of 18.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ATRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 21.50 USD with a low forecast of 18.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.500
Low
18.00
Averages
21.50
High
25.00
Current: 5.500
Low
18.00
Averages
21.50
High
25.00
Canaccord
Buy
maintain
$17 -> $25
2025-12-19
Reason
Canaccord
Price Target
$17 -> $25
AI Analysis
2025-12-19
maintain
Buy
Reason
Canaccord raised the firm's price target on Atara Biotherapeutics to $25 from $17 and keeps a Buy rating on the shares. The firm said they see a reasonable chance for FDA approval of tab-cel in EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) by the upcoming action date of January 11, 2026. The $40M milestone upon approval will help to reinvigorate its pipeline.
Mizuho
Salim Syed
Outperform
maintain
$16 -> $18
2025-11-20
Reason
Mizuho
Salim Syed
Price Target
$16 -> $18
2025-11-20
maintain
Outperform
Reason
Mizuho analyst Salim Syed raised the firm's price target on Atara Biotherapeutics to $18 from $16 and keeps an Outperform rating on the shares. The firm said it raised its price target on decreased operating expense, adding that it is watching the January 10, 2026 PDUFFA date for tab-cel and any word on the company's strategic alternatives valuation.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATRA
Unlock Now
Canaccord Genuity
John Newman
Strong Buy
Maintains
$17
2025-03-11
Reason
Canaccord Genuity
John Newman
Price Target
$17
2025-03-11
Maintains
Strong Buy
Reason
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
